Published in
Taylor & Francis, Expert Opinion on Investigational Drugs, 6(30), p. 665-673, 2021
DOI: 10.1080/13543784.2021.1915986
Links
Tools
Do histone deacytelase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes?
Journal article published in 2021 by
Talha Badar 
,
Ehab Atallah
,
Ehab Atallah
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 